Literature DB >> 28578484

Valbenazine: First Global Approval.

Esther S Kim1.   

Abstract

Valbenazine (Ingrezza™) is an orally bioavailable, selective, vesicular monoamine transporter 2 (VMAT2) inhibitor being developed by Neurocrine Biosciences for the treatment of various central nervous system disorders. Valbenazine has been approved in the USA for the treatment of adults with tardive dyskinesia (TD), is at various stages of development in other countries for TD and is in phase 2 development in the USA for Tourette syndrome. This article summarizes the milestones in the development of valbenazine leading to its first global approval in the USA for the treatment of adults with TD.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28578484     DOI： 10.1007/s40265-017-0770-9

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


  5 in total

1.  Pharmacologic Characterization of Valbenazine (NBI-98854) and Its Metabolites.

Authors:  Dimitri E Grigoriadis; Evan Smith; Sam R J Hoare; Ajay Madan; Haig Bozigian
Journal:  J Pharmacol Exp Ther       Date:  2017-04-12       Impact factor: 4.030

2.  Tardive dyskinesia.

Authors:  Pratibha G Aia; Gonzalo J Revuelta; Leslie J Cloud; Stewart A Factor
Journal:  Curr Treat Options Neurol       Date:  2011-06       Impact factor: 3.598

3.  KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia.

Authors:  Robert A Hauser; Stewart A Factor; Stephen R Marder; Mary Ann Knesevich; Paul M Ramirez; Roland Jimenez; Joshua Burke; Grace S Liang; Christopher F O'Brien
Journal:  Am J Psychiatry       Date:  2017-03-21       Impact factor: 18.112

4.  An update on tardive dyskinesia: from phenomenology to treatment.

Authors:  Olga Waln; Joseph Jankovic
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2013-07-12

5.  NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study.

Authors:  Christopher F O'Brien; Roland Jimenez; Robert A Hauser; Stewart A Factor; Joshua Burke; Daniel Mandri; Julio C Castro-Gayol
Journal:  Mov Disord       Date:  2015-09-08       Impact factor: 10.338
  5 in total
  2 in total

Review 1.  Current Approaches and New Developments in the Pharmacological Management of Tourette Syndrome.

Authors:  Julio Quezada; Keith A Coffman
Journal:  CNS Drugs       Date:  2018-01       Impact factor: 5.749

2.  (+)-9-Trifluoroethoxy-α-Dihydrotetrabenazine as a Highly Potent Vesicular Monoamine Transporter 2 Inhibitor for Tardive Dyskinesia.

Authors:  Wenyan Wang; Guangying Du; Shilan Lin; Jing Liu; Huijie Yang; Dawei Yu; Liang Ye; Fangxia Zou; Hongbo Wang; Rui Zhang; Jingwei Tian
Journal:  Front Pharmacol       Date:  2021-12-07       Impact factor: 5.810
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.